HEP-1 20 MG

HEP-1, also known as Human Ezrin Peptide One (Gepon), is a synthetic tetradecapeptide with significant immunomodulatory, antiviral, and anti-inflammatory properties. It has demonstrated efficacy in treating a wide range of viral infections, including HIV, hepatitis B and C, herpes, HPV, and influenza, while also showing promise in managing chronic inflammation and supporting tissue repair. Clinical studies have reported its ability to reduce viral load, normalize liver enzymes, and enhance adaptive immune responses without significant adverse effects.

• Antiviral Activity: HEP-1 is effective against multiple viruses, including HIV, hepatitis C virus (HCV), herpes simplex virus types 1 and 2, human papillomavirus (HPV), and influenza, by inhibiting viral replication and enhancing the body’s antiviral defenses.

• Immunomodulation: It stimulates humoral immunity by enhancing B cell and T cell responses, leading to increased antibody titers, including after hepatitis B vaccination.

• Anti-inflammatory Effects: HEP-1 suppresses the expression of key inflammatory cytokines such as IL-1, IL-6, IL-8, and TNFα, which helps control excessive inflammation associated with viral infections and autoimmune conditions like systemic lupus erythematosus.

• Tissue Repair and Regeneration: The peptide promotes the repair of damaged epithelial barriers and stimulates fibroblasts to regenerate tissues, making it beneficial for treating ulcers in the gut, skin, and respiratory tract, including those caused by infections or radiation.

• Adjuvant Potential: HEP-1 acts as a potent immune adjuvant, significantly boosting secondary antibody responses in animal models, suggesting its potential use in vaccine development and post-infection immunity support.

• Treatment of Co-infections: In HIV-positive patients, HEP-1 has been successfully used to treat HCV co-infection and opportunistic infections such as mucosal candidiasis, herpes zoster, and chronic diarrhea.

• Potential in Long COVID and Drug Resistance: Preliminary research suggests HEP-1 may help address persistent symptoms in Long COVID and combat drug-resistant strains of bacteria, viruses, and protozoa by modulating immune responses.